全文获取类型
收费全文 | 9693篇 |
免费 | 857篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 139篇 |
儿科学 | 357篇 |
妇产科学 | 252篇 |
基础医学 | 1213篇 |
口腔科学 | 148篇 |
临床医学 | 1244篇 |
内科学 | 1636篇 |
皮肤病学 | 229篇 |
神经病学 | 1285篇 |
特种医学 | 191篇 |
外科学 | 1015篇 |
综合类 | 50篇 |
一般理论 | 16篇 |
预防医学 | 1424篇 |
眼科学 | 102篇 |
药学 | 516篇 |
1篇 | |
中国医学 | 5篇 |
肿瘤学 | 743篇 |
出版年
2024年 | 29篇 |
2023年 | 213篇 |
2022年 | 275篇 |
2021年 | 635篇 |
2020年 | 415篇 |
2019年 | 601篇 |
2018年 | 654篇 |
2017年 | 414篇 |
2016年 | 443篇 |
2015年 | 421篇 |
2014年 | 533篇 |
2013年 | 697篇 |
2012年 | 909篇 |
2011年 | 849篇 |
2010年 | 441篇 |
2009年 | 339篇 |
2008年 | 486篇 |
2007年 | 423篇 |
2006年 | 417篇 |
2005年 | 346篇 |
2004年 | 263篇 |
2003年 | 221篇 |
2002年 | 228篇 |
2001年 | 26篇 |
2000年 | 13篇 |
1999年 | 27篇 |
1998年 | 32篇 |
1997年 | 23篇 |
1996年 | 27篇 |
1995年 | 17篇 |
1994年 | 15篇 |
1993年 | 19篇 |
1992年 | 10篇 |
1991年 | 9篇 |
1990年 | 9篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1987年 | 4篇 |
1986年 | 6篇 |
1985年 | 6篇 |
1984年 | 3篇 |
1983年 | 5篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 7篇 |
1979年 | 7篇 |
1977年 | 3篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1971年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Olivia A. Do Lorin A. Ferris Sarah K. Holt Jorge D. Ramos Lauren C. Harshman Elizabeth R. Plimack Simon J. Crabb Sumanta K. Pal Ugo De Giorgi Sylvain Ladoire Jack Baniel Andrea Necchi Ulka N. Vaishampayan Aristotelis Bamias Joaquim Bellmunt Sandy Srinivas Tanya B. Dorff Matt D. Galsky Evan Y. Yu 《Clinical genitourinary cancer》2021,19(2):125-134
BackgroundOptimal chemotherapy for patients who received cisplatin for localized urothelial carcinoma (UC) and develop metastatic disease is unclear. We compared the efficacy of platinum-based (PBC) versus non–platinum-based (NPBC) first-line chemotherapy for metastasis.Patients and MethodsData were collected from the Retrospective International Study of Cancers of the Urothelial Tract (RISC), a database of 3024 patients from 28 international academic centers from 2005 to 2012. Patient inclusion criteria included: (1) predominant UC; (2) any primary tumor site; (3) cT2-4, cN0-N2, cM0; (4) prior receipt of perioperative/radiation cisplatin-containing chemotherapy; and (5) receipt of cytotoxic chemotherapy in the first-line metastatic setting. Multivariate Cox proportional hazards models were used to show progression-free survival (PFS) and overall survival (OS) from the first day of chemotherapy for metastatic disease to date of censor.ResultsEligibility criteria was met by 132 patients (n = 74 PBC; n = 58 NPBC). The median OS was 8.13 months (interquartile range, 4.87-16.64 months) and 8.77 months (interquartile range, 4.01-13.49 months) for PBC and NPBC, respectively. Neither OS (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.64-1.69; P = .87) nor PFS (HR, 0.86; 95% CI, 0.56-1.31; P = .48) differed for PBC versus NPBC. However, for patients who received chemotherapy more than a year after perioperative/radiation chemotherapy, OS was superior for PBC over NPBC (HR, 0.31; 95% CI, 0.10-0.92; P = .03).ConclusionsThere is no significant outcome difference between PBC and NPBC in patients with metastatic UC who previously received cisplatin-based chemotherapy for localized disease. However, if over a year has elapsed, return to PBC is associated with superior OS. 相似文献
992.
McLemore Lauren E. Albarracin Constance T. Gruschkus Stephen K. Bassett Roland L. Wu Yun Dhamne Sagar Yim Isaiah Lin Kevin Bedrosian Isabelle Sneige Nour Chen Hui 《Breast cancer research and treatment》2021,187(1):95-104
Breast Cancer Research and Treatment - HER2 overexpression and gene amplification are routinely tested by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively. In... 相似文献
993.
994.
995.
Lauren E. Winquist Michael Sanatani Richard B. Kim Eric Winquist 《Current oncology (Toronto, Ont.)》2021,28(1):94
5-fluorouracil (5-FU) and its pro-drug capecitabine are widely used anticancer agents. Most 5-FU catabolism is dependent on dihydropyrimidine dehydrogenase (DPD) encoded by the DPYD gene, and DPYD variants that reduce DPD function increase 5-FU toxicity. Most DPD deficient patients are heterozygous and can be treated with reduced 5-FU dosing. We describe a patient with a genotype associated with near complete absence of DPD function, and severe and likely fatal toxicity with 5-FU treatment. The patient was treated effectively with alternative systemic therapy. Routine pretreatment DPYD genotyping is recommended by the European Medicines Agency, and guidelines for use of 5-FU in DPD deficient patients are available. However, outside the province of Quebec, routine pretreatment screening for DPD deficiency remains unavailable in Canada. It is likely our patient would have died from 5-FU toxicity under the current standard of care, but instead provides an example of the potential benefit of DPYD screening on patient outcomes. 相似文献
996.
997.
998.
Kenneth W. Dodd Rebecca L. Kornas Matthew E. Prekker Lauren R. Klein Robert F. Reardon Brian E. Driver 《The Journal of emergency medicine》2017,52(4):403-408
Background
Removal of a functioning King laryngeal tube (LT) prior to establishing a definitive airway increases the risk of a “can't intubate, can't oxygenate” scenario. We previously described a technique utilizing video laryngoscopy (VL) and a bougie to intubate around a well-seated King LT with the balloons deflated; if necessary, the balloons can be rapidly re-inflated and ventilation resumed.Objective
Our objective is to provide preliminary validation of this technique.Methods
Emergency physicians performed all orotracheal intubations in this two-part study. Part 1 consisted of a historical analysis of VL recordings from emergency department (ED) patients intubated with the King LT in place over a two-year period at our institution. In Part 2, we analyzed VL recordings from paired attempts at intubating a cadaver, first with a King LT in place and then with the device removed, with each physician serving as his or her own control. The primary outcome for all analyses was first-pass success.Results
There were 11 VL recordings of ED patients intubated with the King LT in place (Part 1) and 11 pairs of cadaveric VL recordings (Part 2). The first-pass success rate was 100% in both parts. In Part 1, the median time to intubation was 43 s (interquartile range [IQR] 36–60 s). In Part 2, the median time to intubation was 23 s (IQR 18–35 s) with the King LT in place and 17 s (IQR 14–18 s) with the King LT removed.Conclusions
Emergency physicians successfully intubated on the first attempt with the King LT in situ. The technique described in this proof-of-concept study seems promising and merits further validation. 相似文献999.
1000.